Details

Autor(en) / Beteiligte

• Hanke, Katharina
• Dähnrich, Cornelia
• Brückner, Claudia S
• Huscher, Dörte
• Becker, Mike
• Jansen, Anthonina
• Meyer, Wolfgang
• Egerer, Karl
• Hiepe, Falk
• Burmester, Gerd R
• Schlumberger, Wolfgang
• Riemekasten, Gabriela

Titel

Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort

Ist Teil von

• Arthritis research & therapy, 2009-01, Vol.11 (1), p.R28-R28

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2009

Link zum Volltext

Quelle

SpringerLink (Online service)

Beschreibungen/Notizen

• In the present study, the detection of anti-topoisomerase I (anti-topo I) autoantibodies was evaluated for diagnosis and risk assessment of systemic sclerosis (SSc) patients in a well characterized large monocentric cohort. Sera from patients with SSc (diffuse n = 96, limited n = 113), from patients with overlap syndromes (n = 51), from patients with other diseases associated with SSc (n = 20), as well as from disease controls (n = 487) were analysed for the presence of anti-topo I antibodies by line immunoblot assay and ELISA. Assessment of organ manifestations was performed as proposed by the European Scleroderma Trial and Research network. The applied test systems for the detection of anti-topo I antibodies revealed a diagnostic sensitivity for SSc of approximately 24% and a diagnostic specificity of at least 99.6%. The sensitivity to identify patients with diffuse SSc amounted to 60%. Patients with anti-topo I antibodies showed a higher burden of skin and lung fibrosis, contractures, electrocardiogram changes, as well as digital ulcers and had more active disease than antibody-negative patients. Signal strengths correlated only weakly with disease activity, with modified Rodnan skin score, with predicted forced vital capacity, and with predicted diffusion capacity levels (P = 0.01, rho = 0.234, rho = 0.413, rho = -0.215, rho = -0.219). High signal intensities were associated with an increased mortality in diffuse SSc patients (P = 0.003). Diagnosis and risk assessment of SSc patients can be supported by the detection of anti-topo I antibodies. Signal intensities as obtained by line immunoblot assay or ELISA can be used as a surrogate marker for fibrosis, active disease and worse prognosis.